Carnitine deficiency in children and adolescents with type 1 diabetes

被引:41
作者
Mamoulakis, D [1 ]
Galanakis, E [1 ]
Dionyssopoulou, E [1 ]
Evangeliou, A [1 ]
Sbyrakis, S [1 ]
机构
[1] Univ Crete, Dept Paediat, Iraklion 71500, Greece
关键词
adolescence; camitine; children; diabetic complications; type; 1; diabetes;
D O I
10.1016/S1056-8727(03)00091-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Carnitine is essential for the lipid and carbohydrate metabolism, and proper metabolic control in type 1 diabetes has potential impact on long-term complications. The plasma total, free, and acylcarnitine levels in 47 children and adolescents with type 1 diabetes were determined by a radioisotopic assay and compared to the values of a series of anthropometric measurements and metabolic parameters, including blood glycosylated hemoglobin Alc, serum cholesterol and triglycerides, and urine tnicroalbumin levels. Plasma values for total, free, and acylcarnitine were 30.1 +/- 7.26, 20.0 +/- 4.50, and 10.2 +/- 6.47 mumol/l, respectively. Acyl/free carnitine ratio was 0.544 +/- 0.369. Individuals with type 1 diabetes had significantly lower total and free carnitine levels and significantly higher acyl/free carnitine ratios than controls (P<.001). Plasma total and free carnitine levels were inversely correlated to the duration of diabetes (P=.036 and P=.071, respectively). No statistical relationship was documented between carnitine levels and the remaining anthropometric and metabolic variables. In conclusion, total and free carnitine levels are decreased in children and adolescents with type 1 diabetes. This reduction is time related and may have potential interactions with the long-term complications of type 1 diabetes. Larger studies are required for final conclusions to be drawn on the precise role of carnitine and the possible benefit, if any, of carnitine supplementation in diabetic patients. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:271 / 274
页数:4
相关论文
共 20 条
  • [1] L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment
    Athanassakis, I
    Mouratidou, M
    Sakka, P
    Evangeliou, A
    Spilioti, M
    Vassiliadis, S
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (9-10) : 1813 - 1822
  • [2] CARNITINE ESTERS IN METABOLIC DISEASE
    BOHLES, H
    EVANGELIOU, A
    BERVOETS, K
    ECKERT, I
    SEWELL, A
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1994, 153 (07) : S57 - S61
  • [3] Giannacopoulou C., 1998, Clinical and Experimental Obstetrics and Gynecology, V25, P42
  • [4] PROPERTIES OF CARNITINE TRANSPORT IN RAT-KIDNEY CORTEX SLICES
    HUTH, PJ
    SHUG, AL
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 602 (03) : 621 - 634
  • [5] Bodyweight gain and anticonvulsants - A comparative review
    Jallon, P
    Picard, F
    [J]. DRUG SAFETY, 2001, 24 (13) : 969 - 978
  • [6] Diabetic cardiomyopathy and carnitine deficiency
    Malone, JI
    Schocken, DD
    Morrison, AD
    Gilbert-Barness, E
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1999, 13 (02) : 86 - 90
  • [7] Mantzagrioti-Meimarides M, 1986, PEDIATRIKI, V49, P1
  • [8] Toward a wholly nutritional therapy for type 2 diabetes
    McCarty, MF
    [J]. MEDICAL HYPOTHESES, 2000, 54 (03) : 483 - 487
  • [9] MCGARRY JD, 1976, J LIPID RES, V17, P277
  • [10] NICHOLSON JF, 2000, NELSON TXB PEDIAT, P2181